Heimberger, A. B., Archer, G. E., McLendon, R. E., Price, D., Friedman, A. H., Friedman, H. S., … Sampson, J. H. (2000). Oral administration of the specific EGFR tyrosine kinase inhibitor, ZD1839 (Iressa (TM)), is active against EGFR-overexpressing intracranial tumors. CLINICAL CANCER RESEARCH, 6, 4542S-4543S.

Heimberger, A. B., G. E. Archer, R. E. McLendon, D. Price, A. H. Friedman, H. S. Friedman, D. D. Bigner, and J. H. Sampson. “Oral administration of the specific EGFR tyrosine kinase inhibitor, ZD1839 (Iressa (TM)), is active against EGFR-overexpressing intracranial tumors.” CLINICAL CANCER RESEARCH 6 (November 1, 2000): 4542S-4543S.

Heimberger AB, Archer GE, McLendon RE, Price D, Friedman AH, Friedman HS, et al. Oral administration of the specific EGFR tyrosine kinase inhibitor, ZD1839 (Iressa (TM)), is active against EGFR-overexpressing intracranial tumors. CLINICAL CANCER RESEARCH. 2000 Nov 1;6:4542S-4543S.

Heimberger, A. B., et al. “Oral administration of the specific EGFR tyrosine kinase inhibitor, ZD1839 (Iressa (TM)), is active against EGFR-overexpressing intracranial tumors.” CLINICAL CANCER RESEARCH, vol. 6, AMER ASSOC CANCER RESEARCH, Nov. 2000, pp. 4542S-4543S.

Heimberger AB, Archer GE, McLendon RE, Price D, Friedman AH, Friedman HS, Bigner DD, Sampson JH. Oral administration of the specific EGFR tyrosine kinase inhibitor, ZD1839 (Iressa (TM)), is active against EGFR-overexpressing intracranial tumors. CLINICAL CANCER RESEARCH. AMER ASSOC CANCER RESEARCH; 2000 Nov 1;6:4542S-4543S.